Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 9;12(5):ofaf218.
doi: 10.1093/ofid/ofaf218. eCollection 2025 May.

Serosurveillance to Support HPV Vaccination in England

Kavita Panwar  1 , Kazutomo Yokoya  1 , Marta Checchi  2 , Anja Anderson  2 , Simon Tonge  3 , Ray Borrow  3 , Kate Soldan  2 , Simon Beddows  1   2
Affiliations

Serosurveillance to Support HPV Vaccination in England

Kavita Panwar et al. Open Forum Infect Dis. .

Abstract

Background: In 2020, the World Health Organization (WHO) declared a global strategy to accelerate the elimination of cervical cancer as a public health problem, for which high vaccination coverage rates are a key component. Since its inception in 2008, the UK national adolescent human papillomavirus (HPV) vaccination program has changed the vaccines being offered, the dosing regimen, and has become gender neutral.

Methods: We conducted serosurveillance to evaluate the magnitude and durability of vaccine-induced humoral immunity across various schedule changes, including changing from the bivalent to the quadrivalent vaccine, changes from a 3-dose to 2-dose schedule and inclusion of boys. It does not yet cover more recent schedule changes that include the nonavalent vaccine. Serostatus and antibody levels (in IU/mL) are reported for all nonavalent vaccine types.

Results: Our findings are consistent with data from clinical trials supporting durability of high vaccine-induced antibody levels through to adulthood (into the peak ages of exposure to sexually transmitted infections) and comparability between males and females.

Conclusions: These data support the utility of serosurveillance to monitor population level immunity to inform and evaluate national HPV vaccination programs. This ongoing serosurveillance aims to identify any reductions in vaccine-induced immunity that could foretell of a potential weakening in HPV control.

Keywords: antibody; human papillomavirus; serosurveillance; vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts.

References

    1. Markowitz LE, Schiller JT. Human papillomavirus vaccines. J Infect Dis 2021; 224(12 Suppl 2):S367–s78. - PMC - PubMed
    1. UK Health Security Agency. Human papillomavirus (HPV) vaccine coverage estimates in England: 2022 to 2023. Available at: https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccin.... Accessed December 10, 2024.
    1. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. ISBN 978-92-4-001410-7. Geneva; 2020.
    1. Panwar K, Godi A, Cocuzza CE, et al. Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine 2022; 40:1198–202. - PubMed
    1. Kemp TJ, Panicker G, Eklund C, et al. WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58. NPJ Vaccines 2024; 9:165. - PMC - PubMed

LinkOut - more resources